SCHEMBL732787

SCHEMBL732787

CCC/C(C(C)=O)=C(\C)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 2/20 0.54
FNTB P49356 2/20 0.54
THRB P10828 1/20 0.54
PGGT1B P53609 1/20 0.54
HDAC3 O15379 4/20 0.43
HDAC1 Q13547 4/20 0.43
HDAC2 Q92769 4/20 0.43
HDAC8 Q9BY41 4/20 0.43
FFAR3 O14843 3/20 0.43
CES1 P23141 2/20 0.39
CES2 O00748 1/20 0.39
TSHR P16473 4/20 0.36
ALDH1A1 P00352 3/20 0.35
AKR1B1 P15121 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
PPARG P37231 5/20 0.32
PPARD Q03181 5/20 0.32
PPARA Q07869 5/20 0.32
HDAC11 Q96DB2 4/20 0.32
GPR84 Q9NQS5 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL555677 0.87 FNTA (0.68) FNTAFNTBTHRBPGGT1BHDAC3
SCHEMBL555674 0.87 FNTA (0.68) FNTAFNTBTHRBPGGT1BHDAC3
SCHEMBL166087 0.87 FNTA (0.68) FNTAFNTBTHRBPGGT1BHDAC3
SCHEMBL1300976 0.83 FNTA (0.52) FNTAFNTBTHRBPGGT1BHDAC3
SCHEMBL17010800 0.80 ALDH1A1 (0.50) FNTAFNTBTHRBPGGT1BALDH1A1
SCHEMBL6695771 0.80 FNTA (0.43) FNTAFNTBTHRBPGGT1BALDH1A1
SCHEMBL2547697 0.79 FNTA (0.46) FNTAFNTBTHRBPGGT1BFFAR3
SCHEMBL2122443 0.78 FNTA (0.47) FNTAFNTBTHRBPGGT1BHDAC3
SCHEMBL25269291 0.76 CES1 (0.45) FNTAFNTBTHRBPGGT1BHDAC3
Pyruvate SCHEMBL11244266 0.76 FFAR3 (0.77) HDAC3HDAC1HDAC2HDAC8FFAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658211-B2 Polyconjugates for in vivo delivery of polynucleotides Arrowhead Madison Inc. (US) 2014-02-25 US disclosed
US-8658211-B2 Polyconjugates for in vivo delivery of polynucleotides Arrowhead Madison Inc. (US) 2014-02-25 US disclosed
US-20120230938-A1 Polyconjugates for In Vivo Delivery of Polynucleotides Arrowhead Madison Inc. (US) 2012-09-13 US disclosed
US-8137695-B2 Transferring interfering RNA sequences into cells via conjugation with physiologically labile bond associated with polyamine and/or polyvinyl ether Arrowhead Madison Inc. (US) 2012-03-20 US disclosed
US-8138383-B2 For cellular delivery; heterogeneity polymer containing cationic groups and hydrophobic groups Arrowhead Madison Inc. (US) 2012-03-20 US disclosed
US-8017109-B2 Cellular deivery, random polyacrylate with multiple hydrophobic monomer ROCHE MADISON INC. (US) 2011-09-13 US disclosed
US-8008355-B2 Delivering nucleic acids to cells; copolymer containing amine monomer and hydrophobic segments ROCHE MADISON INC. (US) 2011-08-30 US disclosed
US-7985406-B2 For cellular delivery; heteropolymer containing amine containing monomer and hydrophobic monomers ROCHE MADISON INC. (US) 2011-07-26 US disclosed
US-20090048410-A1 Membrane Active Heteropolymers Arrowhead Pharmaceuticals, Inc. 2009-02-19 US disclosed
US-20090023890-A1 Membrane Active Heteropolymers Arrowhead Pharmaceuticals, Inc. 2009-01-22 US disclosed
US-20080287630-A1 Endosomolytic Poly(Acrylate) Polymers Arrowhead Pharmaceuticals, Inc. 2008-11-20 US disclosed
US-20080287628-A1 Endosomolytic Poly(Vinyl Ether) Polymers Arrowhead Madison Inc. 2008-11-20 US disclosed
US-20080281044-A1 Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers ROCHE MADISON INC. 2008-11-13 US disclosed
US-20080281041-A1 Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol Arrowhead Madison Inc. 2008-11-13 US disclosed
US-20080269450-A1 Endosomolytic Poly-Beta-Aminoester Polymers ROCHE MADISON INC. 2008-10-30 US disclosed
US-20080152661-A1 Polyconjugates for In Vivo Delivery of Polynucleotides Arrowhead Pharmaceuticals, Inc. 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120230938-A1 Polyconjugates for In Vivo Delivery of Polynucleotides PHAX, NCL, PCBP1 FNTA 1870/4885FNTB 1247/4885THRB 3188/4885
US-20080152661-A1 Polyconjugates for In Vivo Delivery of Polynucleotides PHAX, PCBP1, NCL FNTA 1771/4885FNTB 1176/4885THRB 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.